Завершено
Фаза IV
Россия
Raltegravir; Abacavir/Lamivudine · Central Institute of Epidemiology, Moscow, Russia
Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART- naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy